Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. IDL Diagnostics AB's EBITDA for the
three
months ended in Mar. 2026 was €0.12 Mil. IDL Diagnostics AB's Revenue for the
three
months ended in Mar. 2026 was €1.55 Mil. Therefore, IDL Diagnostics AB's EBITDA margin for the quarter that ended in Mar. 2026 was 7.92%.
IDL Diagnostics AB (FRA:80R) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
IDL Diagnostics AB EBITDA Margin % Related Terms
IDL Diagnostics AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:80R vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (FRA:80R) has a EBITDA Margin % of 7.92% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDL Diagnostics AB and its competitors. According to the industry distribution chart, IDL Diagnostics AB ranks #150 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 73.9%.
Is IDL Diagnostics AB's EBITDA Margin % too high?
IDL Diagnostics AB's current EBITDA Margin % is 7.92%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. IDL Diagnostics AB's value of 7.92% is 58.4% above this industry median. Based on the distribution chart, IDL Diagnostics AB ranks #150 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDL Diagnostics AB has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #150 out of 203 companies for EBITDA Margin %. This places IDL Diagnostics AB in the lower half of its industry. The industry median EBITDA Margin % is 5.00. IDL Diagnostics AB's value of 7.92% is 58.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDL Diagnostics AB's current EBITDA Margin % of 7.92% is 58.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDL Diagnostics AB and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDL Diagnostics AB's current EBITDA Margin % is 7.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
IDL Diagnostics AB (FRA:80R) has a current EBITDA Margin % of 7.92%. The stock's GF Value™ is €0.03, compared to a current price of €0.03 — trading 14.7% below its estimated fair value. The current EBITDA Margin % is 7.92% and 58.4% above the Medical Diagnostics & Research industry median of 5.00. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IDL Diagnostics AB (FRA:80R), the current EBITDA Margin % is 7.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (FRA:80R) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of €0.03 is trading 14.7% below its estimated GF Value™ of €0.03.
Key valuation signals for FRA:80R:
EBITDA Margin %: 7.92%
GF Value™: €0.03 vs. price of €0.03 (14.7% below fair value)
Industry Position: 58.4% above the Medical Diagnostics & Research median (#150 of 203)
No single metric tells the full story. See the FRA:80R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score
Get the complete analysis for FRA:80R
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:80R has been successfully added to your 
